TRUSTFULL
26.3.2024 21:20:28 CET | Business Wire | Press release
Trustfull, a leading risktech platform utilizing silent checks on phone, email, IP address, and device intelligence to combat fraud across onboarding, authentication, and payments, announces the appointment of Jim Greenwell as Executive Advisor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326786868/en/
Jim Greenwell (Photo: Business Wire)
Greenwell joins the company with deep experience in the digital identity and mobility space, most recently serving as an executive adviser to Thomson Reuters and AuthenticID, as well as serving on the advisory boards of Prove and Gravy Analytics. Jim is the former CEO of Danal, Inc., having led the company’s growth and innovation within the mobile identity and authentication space for over a decade through its sale to Boku, Inc. (LON: BOKU) in 2019. During his tenure, Jim created successful global partnerships and enduring customer relationships in a broad range of industries, including financial services, government, e-commerce, and wireless. One World Identity recognized Jim as one of the top four CEOs in Identity and Authentication in 2018 and one of the “Top 100 Influencers in Identity” in 2019.
Prior to Danal, Jim was CEO and President at ACE*COMM Corporation focusing on Telecom OSS/BSS software. Prior to ACE*COMM, Jim was the COO/SVP of the Americas and AsiaPac for LCC International where he grew the mobile network design business. Jim began his career as a military intelligence officer in the U.S. Army where he served in Northern Iraq and Turkey as part of the Kurdish relief effort following Desert Storm.
In his role as Executive Advisor, Greenwell will collaborate closely with Trustfull's leadership team to further enhance the platform's capabilities and drive its expansion into new markets.
Commenting on the appointment, Trustfull CEO Marko Maras said, "We are thrilled to welcome Jim to Trustfull as our Executive Advisor. His deep understanding of the industry and proven track record of driving growth and innovation will be invaluable as we continue to empower businesses with advanced fraud prevention solutions."
Jim Greenwell also expressed his enthusiasm about joining Trustfull, stating, "I am honored to join Trustfull as Executive Advisor. The company's commitment to leveraging cutting-edge technology to combat fraud is truly impressive, and I look forward to working closely with the team to further strengthen Trustfull's position as a leader in the industry."
Greenwell's appointment comes at a pivotal time for Trustfull as it continues to innovate and expand its suite of fraud prevention solutions, helping businesses mitigate risks and protect their assets in an increasingly digital landscape.
About Trustfull
Trustfull is a cloud-based digital risk intelligence platform. Utilizing silent checks on multiple signals including phone number, email address, IP address, device, and browser, Trustfull helps companies across different industries assess risks an provide a safer online experience. Main use cases include: KYC, AML, Account Takeover, Promo Abuse and Transaction Monitoring.
For more information: http://www.trustfull.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326786868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom